eFFECTOR Increases Its Series B Financing Round To $56M

SAN DIEGO, Feb. 19, 2016 /PRNewswire/ -- eFFECTOR Therapeutics, Inc., a biopharmaceutical company developing selective translation regulators for the treatment of cancer, today announced it has increased its Series B financing to a total of $56M. The new funding came from Sectoral Asset Management, a new investor in the syndicate, as well as existing investors. In conjunction with the increase, eFFECTOR has appointed Maha Katabi, Ph.D., CFA, partner, private equity at Sectoral Asset Management, to its board of directors. These developments further position eFFECTOR to pursue comprehensive clinical development of its lead product candidate, eFT508, a potent, highly selective, and orally bioavailable MNK1 and MNK2 inhibitor, across multiple tumor types. The funds will also be used to advance the company's discovery pipeline addressing additional targets.

eFFECTOR Therapeutics logo

eFT508 is currently being evaluated in an open-label Phase 1/2 trial in patients with advanced solid tumors.  The company expects to file a second IND for eFT508 in lymphoma in the first half of 2016 and open expansion arms in specific solid tumors as well as lymphoma. The company also plans to declare its second development candidate later this year.

"Cancer has proven to be a very difficult disease," said Steve Worland, Ph.D., president and CEO of eFFECTOR. "If we are going to bring more effective therapy to patients, we need to think strategically about new approaches to treatment. Translation regulation targets such as MNK1 and MNK2, which simultaneously regulate multiple cancer-driving and immune-signaling pathways, are an ideal way to pursue this need. With this financial backing, eFFECTOR can make significant progress developing eFT508 and the remainder of our pipeline."

Added Dr. Katabi, "Sectoral selects investments in healthcare companies developing products that can make a meaningful impact on the patients and healthcare systems they serve. Translation control is one of the most intriguing fields of research in oncology. We are very pleased to work with the experienced team of eFFECTOR to make eFT508 the first pharmacological treatment to affect the gene translation machinery, and develop a drug useful to patients with different types of cancer."

About eFFECTOR Therapeutics

eFFECTOR Therapeutics is pioneering the discovery and development of selective translation regulators as a new class of small molecule therapeutics for cancer. The company's investigational compounds are designed to restore translational control to halt underlying disease mechanisms while preserving healthy physiological processes. eFFECTOR's lead drug candidate, eFT508, is a highly selective MNK1 and MNK2 inhibitor. MNK1 and 2 are kinases that act as signal integrators at the convergence of multiple oncogenic and immune signaling pathways to regulate production of disease-driving proteins. The company has additional translation regulation programs currently in discovery. eFFECTOR has raised $111M in financing from top-tier private and corporate venture funds. For more information visit www.effector.com

Heidi Chokeir, Ph.D.

Logo - http://photos.prnewswire.com/prnh/20150619/224279LOGO


To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/effector-therapeutics-increases-its-series-b-financing-round-to-56m-300222835.html

SOURCE eFFECTOR Therapeutics

Back to news